20,000 Shares in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Acquired by Fifth Third Wealth Advisors LLC

Fifth Third Wealth Advisors LLC purchased a new position in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) in the 1st quarter, Holdings Channel reports. The firm purchased 20,000 shares of the company’s stock, valued at approximately $30,000.

Separately, DCF Advisers LLC grew its stake in shares of Lineage Cell Therapeutics by 14.5% in the fourth quarter. DCF Advisers LLC now owns 94,751 shares of the company’s stock valued at $103,000 after buying an additional 12,000 shares in the last quarter. Institutional investors own 62.47% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Lineage Cell Therapeutics in a research report on Monday, May 6th.

Lineage Cell Therapeutics Price Performance

Shares of LCTX traded down $0.03 during midday trading on Friday, reaching $1.00. 3,302,987 shares of the stock were exchanged, compared to its average volume of 997,696. Lineage Cell Therapeutics, Inc. has a twelve month low of $0.84 and a twelve month high of $1.61.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last released its earnings results on Thursday, May 9th. The company reported ($0.04) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.04). Lineage Cell Therapeutics had a negative return on equity of 34.92% and a negative net margin of 295.59%. The firm had revenue of $1.44 million for the quarter, compared to analysts’ expectations of $2.22 million. On average, equities research analysts predict that Lineage Cell Therapeutics, Inc. will post -0.12 earnings per share for the current fiscal year.

Lineage Cell Therapeutics Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.